Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 953-960

  Vickers, M M ^a   Karapetis, C S ^b   Tu, D ^c   O'Callaghan, C J ^c   Price, T J ^d   Tebbutt, N C ^e   Van Hazel, G ^f   Shapiro, J D ^g   Pavlakis, N ^h   Gibbs, P ⁱ   Blondal, J ^j   Lee, U ^k   Meharchand, J M ^l   Burkes, R L ^m   Rubin, S H ⁿ   Simes, J ^o   Zalcberg, J R ^p   Moore, M J ^q   Zhu, L ^c   Jonker, D J ^r  

^a TOM BAKER CANCER CENTRE   (Canada)

^b FLINDERS MEDICAL CENTRE   (Australia)

^c QUEEN S UNIVERSITY   (Canada)

^d QUEEN ELIZABETH HOSPITAL   (Australia)

^e AUSTIN HEALTH   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g CABRINI INSTITUTE   (Australia)

^h ROYAL NORTH SHORE HOSPITAL   (Australia)

ⁱ ROYAL MELBOURNE HOSPITAL   (Australia)

^j ST JOSEPH S HOSPITAL   (Canada)

^k BCCA   (United Kingdom)

^l TORONTO EAST GENERAL HOSPITAL   (Canada)

^m MOUNT SINAI HOSPITAL   (Canada)

ⁿ MONCTON HOSPITAL   (Canada)

^o UNIVERSITY OF SYDNEY   (Australia)

^p PETER MACCALLUM CANCER CENTRE   (Australia)

^q PRINCESS MARGARET HOSPITAL   (Canada)

^r UNIVERSITY OF OTTAWA   (Canada)

more..

Author keywords

Cetuximab; Colorectal cancer; Epidermal growth factor receptor; Hypomagnesemia; KRAS

Indexed keywords

CETUXIMAB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; CONFUSION; CONSTIPATION; CONTROLLED STUDY; DRUG ERUPTION; DYSPEPSIA; DYSPNEA; EDEMA; FATIGUE; FEMALE; GENE MUTATION; HUMAN; HYPOMAGNESEMIA; INFECTION; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NAUSEA; ONCOGENE K RAS; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SURVIVAL PREDICTION;

EID: 84875608267     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds577     Document Type: Article

References (24)

1. Garrett CR, Eng C. Cetuximab in the treatment of patients with colorectal cancer. Expert Opin Biol Ther 2011; 11: 937-949.
2. Lockhart AC, Berlin JD. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol 2005; 32: 52-60.
3. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
4. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048.
5. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664.
6. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
7. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
8. Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18: 904-914.
9. Saltz LB, Meropol NJ, Loehrer PJ, Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
10. Schrag D, Chung KY, Flombaum C et al. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005; 97: 1221-1224.
11. Tejpar S, Piessevaux H, Claes K et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007; 8: 387-394.
12. Cao Y, Liao C, Tan A et al. Meta-analysis of incidence and risk of hypomagnesemia with cetuximab for advanced cancer. Chemotherapy 2010; 56: 459-465.
13. Groenestege WM, Thebault S, van der Wijst J et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 2007; 117: 2260-2267.
14. Wolf FI, Cittadini AR, Maier JA. Magnesium and tumors: ally or foe? Cancer Treat Rev 2009; 35: 378-382.
15. Nasulewicz A, Wietrzyk J, Wolf FI et al. Magnesium deficiency inhibits primary tumor growth but favors metastasis in mice. Biochim Biophys Acta 2004; 1739: 26-32.
16. Vincenzi B, Santini D, Galluzzo S et al. Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. Clin Cancer Res 2008; 14: 4219-4224.
17. Vincenzi B, Galluzzo S, Santini D et al. Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. Ann Oncol 2011; 22: 1141-1146.
18. Au HJ, Karapetis CS, O'Callaghan CJ et al. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 trial. J Clin Oncol 2009; 27: 1822-1828.
19. Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2311-2319.
20. Van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-2019.
21. Peeters M, Siena S, Van Cutsem E et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 2009; 115: 1544-1554.
22. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFRtargeted agents: is there a silver lining? J Clin Oncol 2005; 23: 5235-5246.
23. 2+ channels in health and disease. J Am Soc Nephrol 2005; 16: 15-26.
24. Dai Q, Shrubsole MJ, Ness RM et al. The relation of magnesium and calcium intakes and a genetic polymorphism in the magnesium transporter to colorectal neoplasia risk. Am J Clin Nutr 2007; 86: 743-751.